Provided by Meniscus Educational Institute and Meniscus Limited

Supported by an educational grant from Lilly USA, LLC.

Release Date: March 2010

CE Available Until: March 31, 2011

Intended Audience
This continuing education activity is designed for oncology nurses and other healthcare providers interested in the care of oncology patients.

Learning Objectives
At the completion of this activity, participants should be better able to  

• Describe the risk factors for venous thromboembolism in the patient with colorectal cancer (CRC)
• List three agents commonly administered to patients with CRC that may contribute to hypercoagulability
• Define the role of low molecular weight heparin in the treatment of venous thromboembolism in patients with CRC

Rationale and Purpose
Venous thromboembolism (VTE) is a known complication of cancer; approximately 15% of patients with cancer will develop a VTE. For some patients without cancer, a diagnosis of thrombosis may predict the development of a malignancy. Patients with VTE may also have reduced survival. Despite publication of guidelines, prevention and therapeutic measures for VTE continue to be under utilized in cancer patients. The goal of this educational activity is to close existing learning gaps and improve the prevention, diagnosis, and management of VTE in patients with cancer in order to improve patient outcomes and quality of life.

Continuing Education
Statement of Credit—To successfully complete this activity, you must review the content, score at least a 70% on the learning assessment, and submit your evaluation form. If you provide your e-mail address, you will receive an immediate e-mail notification with a link to your printable statement of credit.

 Nurses. This activity for 0.5 contact hours is provided by the Meniscus Educational Institute.

The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.


Accreditation refers to recognition of educational activities only and does not imply approval or endorsement by the Meniscus Educational Institute or the American Nurses Credentialing Center’s Commission on Accreditation of any product mentioned.

Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 0.5 contact hours.

Financial Disclosures
All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity. All faculty have been offered a modest honorarium from the accredited provider for their participation in this activity.

Financial disclosures for all parties who developed or reviewed content.

Susan Moore, RN, MSN, ANP, AOCN®, Advisory Panel, receives an honorarium from Genentech, Inc.
Pamela Hallquist Viale, RN, MS, CS, ANP, AOCNP®, Advisory Panel, receives honoraria from Bristol-Myers Squibb Company, Amgen Inc., Merck & Co., and Novartis Pharmaceuticals Corporation.
Carolyn Grande, MSN, CRNP, AOCNP®, Advisory Panel, receives an honorarium from IMER. 
Linda J. Smith, MSN, MEd, Project Director, has nothing to disclose.
Karen J. Abbas, RN, MS, AOCN®, Nurse Planner, has nothing to disclose.
Karen Dow Meneses, PhD, RN, FAAN, Content Reviewer, has nothing to disclose.
Linda Moriarty, RN, BSN, OCN®, Pilot Reviewer, receives honorarium from Merck & Co.
Dawn C. Stefanik, AA, MLT, BSN, RN, OCN®, Pilot Reviewer, has nothing to disclose.

Disclaimer
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.

The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by MEI of any specific therapeutics or approaches to diagnosis or patient management.

Product Disclosure
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the US Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product or consult the latest edition of the Physicians’ Desk Reference.

There is no fee for participating in this activity.

ANCC Accreditation Feedback Line
1-866-262-9730

The Accreditation Program of the American Nurses Credentialing Center is interested in the opinions and perspectives of the participants in accredited continuing nursing education activities, particularly perspectives related to the presence of perceived bias* in an activity. For this reason, we provide a toll-free telephone number, which participants may call at any time to tell us about   

• Any noted bias or conflict of interest in the education
• Any concerns, compliments, or opinions
• A great experience
• An unpleasant experience
• Your thoughts on the process

Just call and tell us!
1-866-262-9730
*Bias is defined as preferential influence that causes a distortion of opinion or facts. Commercial bias may occur when an educational activity promotes one or more product(s) (drugs, devices, services, software, hardware, etc). This definition is not all inclusive, and participants may use their own interpretation in deciding whether a presentation is biased.
NOTE: statements of commercial support and/or conflict of interest disclosures do not represent bias. Such statements inform the learner that the provider has implemented a mechanism to identify and resolve all conflicts of interest prior to delivery of the educational material.

Download Activity
By selecting the link below you acknowledge that you have read the CE information and would like to proceed with the activity.

Instructions for Completion
To successfully complete this activity and receive continuing education credit, you must read the text and score at least 70% on the learning assessment, and complete the evaluation form. You can access the learning assessment and evaluation form by selecting the link below. If you provide your e-mail address, you will receive an immediate e-mail notification with a link to your printable statement of credit.